Grifols maintains a long history of commitment to science and research dating back to the 1940s. The global Investigator Sponsored Research (ISR) program is exemplary of this commitment. The program provides support to external researchers who have an interest in advancing scientific knowledge in therapeutic areas that are strategically aligned with Grifols’ business interests.
ISR studies are unsolicited, independent research which generally are hypothesis generating and/or provide proof of concept data. They may be pre-clinical, clinical in vivo and/or ex vivo, or retrospective data analysis studies, and are designed to answer questions that clinicians face in their day-to-day practice. The non-Grifols partner acts as the Sponsor and Grifols provides support to conduct the research.
Grifols is focused on treating conditions across a broad range of therapeutic areas:
Please contact us by completing the Contact Form below to obtain Grifols ISR Concept Form. Please note, you will first need to complete a concept form before a full proposal is requested.
Yes, you must first submit a completed concept form and CVs of all study staff. If your study concept meets Grifols criteria, you will be invited to submit a full research proposal for evaluation by the ISR Review Committee. If you are interested in submitting a research concept, please complete the Contact Form below and our team will reach out to you.
Yes, each submission must include the completed submission form and an up-to-date curriculum vitae (CV) for all study staff listed on the submission form.
There are typically two ISR Review cycles each year during which ISR proposal submissions are evaluated for potential funding by the ISR Review Committee.
This form is for Grifols ISR Program inquiries only. It should not be used for submitting business development ideas, supplier inquiries or media questions. Please refer to the dedicated areas at www.grifols.com for these interests. Thank you for your understanding.
We’ll find the best therapeutic option for patients, be it plasma or non-plasma, to treat their diseases and make their lives more productive and fulfilling